Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer

This study has been terminated.
(slow enrollment)
Information provided by (Responsible Party):
Ruth He, Georgetown University Identifier:
First received: April 13, 2009
Last updated: March 23, 2014
Last verified: March 2014
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: June 2013
  Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)